Search is Powered by Google
Cancer / Oncology News

Cutting-Edge Epigenome Center At USC Supported By $10 Million Gift

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 03 Oct 2007 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:2 stars

2 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

The Keck School of Medicine of the University of Southern California (USC) received a $10 million gift from the Kenneth T. & Eileen L. Norris Foundation that will be critical in launching one of the nation's first research centers devoted to the study of epigenetics.

The grant will solidify USC's position at the forefront of epigenetics research -- a field that holds great promise in the treatment and prevention of cancer, says Peter Jones, Ph.D., director of the USC/Norris Comprehensive Cancer Center at the Keck School.

"This gift is critical to the university because of the large amount of epigenetics research that has already taken place at USC," Jones says. "We've been one of the leaders in the field for some time and the commitment of the Norris Foundation will allow us to expand our capabilities. We shall now be able to use high throughput techniques to sequence entire epigenomes for the first time. Such approaches would have been unthinkable even a short while ago."

Epigenetics is the study of how chemicals that attach to DNA and proteins can switch genes on and off without changing the fundamental genetic information. Understanding how specific genes switch on and off has vast implications for the prevention and treatment of cancer and other diseases. Jones, a past president of the American Association for Cancer Research, says he expects the Epigenome Center at USC will play an integral role in the international epigenome project he is spearheading.

"Most of the research up to now has been focused on genetics," Jones says. "Now, people are starting to realize that epigenetic processes that package the genome are critical to how it can be used in different cells. When the packaging is right, cells work. When it goes wrong disease can occur."

Ronald Barnes, executive director and trustee of the Kenneth T. & Eileen L. Norris Foundation, says he is pleased that the grant will help the university to meet the increasing demands for new, cutting-edge research.

"We are proud to continue our support of the USC/Norris Comprehensive Cancer Center by helping to develop one of the first epigenome centers in the world," he says. "We believe the facility will be critical to the future of cancer research."

Through its foundation, the Norris family has given more than $50 million to USC, naming the USC/Norris Comprehensive Cancer Center, the Eileen L. Norris Cinema Theater, the Norris Dental Center, the Norris Medical Library and the Norris Auditorium.

The Epigenome Center will be housed on the ground floor of the Harlyne J. Norris Cancer Research Tower, a 172,440 square-foot research facility that opened earlier this year at USC's Health Sciences Campus. The center will house state-of-the-art sequencing equipment and computational biologists who will analyze the massive amount of data to be produced. The $10 million gift will go towards acquisition of equipment and staff recruitment.

Peter Laird, a lead researcher and associate professor of surgery, biochemistry and molecular biology, has been named director of the center. A formal opening is planned for January 2008.

In the past year, the center has received five National Cancer Institute grants, five Foundation grants, two California Institute for Regenerative Medicine (CIRM) seed grants and three CIRM basic science grants.

The Norris Foundation's support will position the university to apply for additional funding from the National Institutes of Health, which has launched a Roadmap Epigenetics Program, Jones notes. The program seeks to develop comprehensive reference epigenome maps and new technologies for comprehensive epigenomic analyses throughout the world.

"The grant is a very generous and well-timed gift which allows USC and the Norris Comprehensive Cancer Center to continue its upward trajectory in this field. It contributes directly to the well being of people and patients," Jones says.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Meghan Lewit
University of Southern California




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...